The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia

Acute myeloid leukemia is a heterogeneous disease with a 5-year survival rate of 28.3%, and current treatment options constrained by dose-limiting toxicities. One of the key signaling pathways known to be frequently activated and dysregulated in AML is PI3K/AKT. Its dysregulation is associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Annageldiyev, Charyguly, Tan, Su-Fern, Thakur, Shreya, Dhanyamraju, Pavan Kumar, Ramisetti, Srinivasa R., Bhadauria, Preeti, Schick, Jacob, Zeng, Zheng, Sharma, Varun, Dunton, Wendy, Dovat, Sinisa, Desai, Dhimant, Zheng, Hong, Feith, David J., Loughran, Thomas P., Amin, Shantu, Sharma, Arun K., Claxton, David, Sharma, Arati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140985/
https://www.ncbi.nlm.nih.gov/pubmed/32296637
http://dx.doi.org/10.3389/fonc.2020.00393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140985/
https://www.ncbi.nlm.nih.gov/pubmed/32296637
http://dx.doi.org/10.3389/fonc.2020.00393

Ejemplares similares